BURNABY, British Columbia, April 18, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 22nd Annual Needham Virtual Healthcare Conference taking place April 17-20, 2023.
| Company Fireside Chat Presentation Details: | |
| Date: | Thursday, April 20, 2023 |
| Time: | 2:15 pm Eastern Time (11:15 am Pacific Time) |
| Presenters: | Ian Mortimer, President and CEO |
| Sherry Aulin, CFO | |
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$39.21 |
| Daily Change: | 0.38 0.98 |
| Daily Volume: | 627,415 |
| Market Cap: | US$3.020B |
August 11, 2025 June 03, 2025 May 14, 2025 May 12, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
